Managing the Journey from Process Development to Insight

This webinar shows how Polar, our cloud-based BioPharma Lifecycle Management (BPLM) platform, now makes it possible to operationalize data governance throughout biopharma development, ensuring data integrity while improving efficiency in the lab.

Digital workflows with embedded data and equipment integrations eliminate data silos and provide the full context behind process and quality data, curating a rich data backbone across the biopharmaceutical lifecycle.

Our new Polar Insight capabilities provide advanced data modelling and visualization tools, reducing the reliance on data science experts for common analysis requests such as comparing bioreactor runs or complex data sets over multiple campaigns and creating a more efficient path to process understanding.


Learning outcomes:

  • Learn how to build the right foundation to ensure confidence in the accuracy and availability of your data.
  • Understand how to get actionable insights from your bioprocess data to maximize cell culture productivity.
  • Discover how digital workflows with embedded integrations can curate a process data backbone that speeds time-to-insight with advanced data analytics and visualization tools.

Watch on demand now


Henry Charlton, Commercial Director of Biologics Development

Henry Charlton studied Biochemical Engineering at University College London and subsequently researched harvesting procedures for mammalian cells secreting monoclonal antibodies for his PhD. He has held a number of roles developing and implementing biopharmaceutical manufacturing processes. This included the use of software to understand the implications for manufacturing facility expansions and the impact of various technical options and platforms.

More recently he has focused on solutions to expedite the development of diagnostic tools and biopharmaceuticals based on understanding market drivers and customer opinion. This culminated in him joining IDBS, the leading provider of R&D software solutions for the biopharmaceutical industry, in September 2020 as Commercial Director for Biologics Development.